financetom
Personal Finance
financetom
/
Personal Finance
/
Research Alert: CFRA Raises Opinion On Shares Of Nasdaq, Inc. To Strong Buy From Buy
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Research Alert: CFRA Raises Opinion On Shares Of Nasdaq, Inc. To Strong Buy From Buy
Sep 23, 2025 10:29 AM

01:10 PM EDT, 09/23/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

With shares showing some weakness, we believe now is an excellent time to gain exposure to NDAQ. The company is building momentum as Verafin rapidly signs new clients, due to banks' accelerating demand for financial crime solutions. Additional growth opportunities include expanding relationships with large Tier 1 clients, international market penetration, and cross-selling initiatives. While deals take time to convert to revenue, we expect strong 1H 2025 performance to drive accelerating growth into 2026. Easing tariff concerns should also benefit NDAQ through improved sales cycles and increased IPO activity. Finally, the AI boom provides another tailwind, as continued Tech sector outperformance drives assets under management growth in the Index business. We increase our target price by $10 to $130, applying a forward P/E of 34.1x our 2026 EPS estimate, above NDAQ's five-year average forward P/E of 23.2x. We increase our 2025 EPS estimate by $0.02 to $3.38 and 2026's by $0.08 to $3.81.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Research Alert: CFRA Maintains Buy Opinion On Shares Of Jpmorgan Chase & Co.
Research Alert: CFRA Maintains Buy Opinion On Shares Of Jpmorgan Chase & Co.
Oct 14, 2025
12:20 PM EDT, 10/14/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We keep our 12-month target price at $340, applying a forward P/E of 15.5x, near the three-year historical average at 15.0x on normalized earnings. We keep our EPS estimates at...
Research Alert: CFRA Raises Opinion On Shares Of Johnson & Johnson To Buy From Hold
Research Alert: CFRA Raises Opinion On Shares Of Johnson & Johnson To Buy From Hold
Oct 14, 2025
11:05 AM EDT, 10/14/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: After Q3 earnings and the announcement of the separation of Orthopedics, we raise our target to $220 from $166. This is based on 19.2x our 2026 EPS estimate and is...
Research Alert: CFRA Keeps Strong Buy Opinion On Adss Of Astrazeneca
Research Alert: CFRA Keeps Strong Buy Opinion On Adss Of Astrazeneca
Oct 13, 2025
06:20 AM EDT, 10/13/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We revised our target price to USD98 (up from USD86), which implies 19.3x our 2026 EPADS estimate, largely in line with its five-year historical forward P/E. On October 10, U.S....
Research Alert: CFRA Keeps Hold Opinion On Class B Shares Of Berkshire Hathaway Inc.
Research Alert: CFRA Keeps Hold Opinion On Class B Shares Of Berkshire Hathaway Inc.
Oct 12, 2025
01:00 AM EDT, 10/13/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We raise our 12-month target price by $15 to $510, valuing Berkshire's class B shares at 23x our 2026 operating EPS estimate of $21.80, versus their three-year average forward multiple...
Copyright 2023-2025 - www.financetom.com All Rights Reserved